Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C14H22N2O2 · C4H6O6
CAS Number:
Molecular Weight:
400.42
UNSPSC Code:
41116107
NACRES:
NA.24
grade
pharmaceutical primary standard
API family
rivastigmine
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
N([C@@H](C)c1cc(ccc1)OC(=O)N(CC)C)(C)C.O[C@@H]([C@H](O)C(=O)O)C(=O)O
InChI
1S/C14H22N2O2.C4H6O6/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4;5-1(3(7)8)2(6)4(9)10/h7-11H,6H2,1-5H3;1-2,5-6H,(H,7,8)(H,9,10)/t11-;1-,2-/m00/s1
InChI key
GWHQHAUAXRMMOT-RWALOXMOSA-N
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Rivastigmine for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Biochem/physiol Actions
Rivastigmine is an orally available, brain penetrant, reversible cholinesterase inhibitor that enhances cognitive function in patients with Alzheimer′s and Parkinson′s diseases. Rivastigmine inhibits both butyrylcholinesterase and acetylcholinesterase.
Rivastigmine is an orally available, brain penetrant, reversible cholinesterase inhibitor.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 2 Oral - Aquatic Chronic 2
Storage Class
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Katherine L Possin et al.
Movement disorders : official journal of the Movement Disorder Society, 28(10), 1384-1390 (2013-07-13)
The objective of this study was to investigate how acetylcholinesterase inhibitor (ChEI) treatment affects brain function in Parkinson's disease (PD). Twelve patients with PD and either dementia or mild cognitive impairment underwent task-free functional magnetic resonance imaging before and after
Kevin R Peters
Journal of the American Geriatrics Society, 61(7), 1170-1174 (2013-05-29)
To highlight the utility of using an effect size analysis to communicate the effectiveness of treatment interventions. Secondary analysis. Previously published systematic review on cholinesterase inhibitors (ChEIs) in Alzheimer's disease. Individuals with mild to moderate Alzheimer's disease. Six-month randomized controlled
Nastaran Majdi Nasab et al.
JPMA. The Journal of the Pakistan Medical Association, 62(7), 677-680 (2013-07-23)
To assess the efficacy of the Ginkgo biloba in patients with dementia of the Alzheimer type in slowing down the disease's degenerative progression and the patients' cognitive impairment compared with rivastigmine. Total 56 patients aged 50-75 years, suffering from dementia